Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

CD47 Expression Defines the Efficacy of Rituximab in Non-Germinal Center B-Cell (non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Tom Van Meerten, Renee Bouwstra, Bsc, Yuan He, PhD, de Boer Janneke, Bsc, Hilde Kooistra, MD PhD, Rudolf Fehrmann, MD PhD, Emanuele Ammatuna, MD PhD, Gerwin Huls, MD PhD, Edwin Bremer, PhD

Blood (2018) 132 (Supplement 1): 2852.

https://doi.org/10.1182/blood-2018-99-114561

Published: 2018

Journal Articles

Temsirolimus, An mTOR Inhibitor, In Combination with Low-Dose Clofarabine in Older Patients with Advanced Acute Myeloid Leukemia: Results of a Phase 2 GIMEMA Study (AML-1107)

Sergio Amadori, MD, Adriano Venditti, MD, Emanuele Ammatuna, MD, Alberto M. Martelli, MD, Giovanna Meloni, MD, Fabrizio Pane, MD, Giovanni Martinelli, MD, Monia Lunghi, Livio Pagano, MD, Daniela Cilloni, MD, PhD, Vittorio Rizzoli, Francesco Di Raimondo, MD, Claudio Fozza, MD, Luciana Annino, MD, Alfonso Piciocchi, Edoardo La Sala, Paola Fazi, MD, Marco Vignetti, MD

Blood (2010) 116 (21): 510.

https://doi.org/10.1182/blood.V116.21.510.510

Published: 2010

Journal Articles

Flow-Cytometric Minimal Residual Disease Determination Is a Surrogate Prognosticator in Adult AML Patients Lacking Specific Molecular Signatures.

Francesco Buccisano, MD, Luca Maurillo, MD, Giovanni Del Poeta, MD, Maria Ilaria Del Principe, MD, Daniela Fraboni, PhD, Emanuele Ammatuna, MD, Maria Irno Consalvo, PhD, Paola Panetta, PhD, Licia Ottaviani, MD, Sabrina Faccia, MD, Manuela Rizzo, MD, Massimiliano Postorino, MD, Maria Cantonetti, MD, Francesco Lo Coco, MD, Sergio Amadori, MD, Adriano Venditti, MD

Blood (2007) 110 (11): 3498.

https://doi.org/10.1182/blood.V110.11.3498.3498

Published: 2007

Journal Articles

Detection of Minimal Residual Disease by Flow-Cytometry Otimizes Risk Stratification When Combined with Cytogenetics in AML.

Francesco Buccisano, MD, Luca Maurillo, MD, Giovanni Del Poeta, MD, Maria Ilaria Del Principe, MD, Paola Panetta, PhD, Daniela Fraboni, PhD, Maria Irno Consalvo, PhD, Daniela Renzi, MD, Selenia Campagna, MD, Chiara Sarlo, MD, Luca Franceschini, MD, Laura Giannì, MD, Emanuele Ammatuna, MD, Francesco Lo Coco, MD, Sergio Amadori, MD, Adriano Venditti, MD

Blood (2007) 110 (11): 4242.

https://doi.org/10.1182/blood.V110.11.4242.4242

Published: 2007

Journal Articles

Hepatitis B Virus Reactivation and Alemtuzumab Therapy.

Emilio Iannitto, MD, Viviana Minardi, MD, Giuseppina Calvaruso, MD, Antonino Mulè, MD, Donatella Ferraro, PhD, Emanuele Ammatuna, MD, Antonio Craxì, MD, Vincenzo Abbadessa, MD, Rosellina Di Stefano

Blood (2004) 104 (11): 4816.

https://doi.org/10.1182/blood.V104.11.4816.4816

Published: 2004

Journal Articles

Assessment of the Frequency of Additional Malignancies in Patients with Splenic Marginal Zone Lymphoma (SMZL).

Emilio Iannitto, MD, Stefano De Cantis, PhD, Viviana Minardi, MD, Vincenzo Callea, MD, Giuseppina Calvaruso, MD, Antonino Mulè, MD, Emanuele Ammatuna, MD, Caterina Stelitano, MD, Claudio Tripodo, MD, Achille Ambrosetti, MD, Giovanni Pizzolo, MD, Ada Florena, MD, Vito Franco, MD, Ada Florena, MD

Blood (2004) 104 (11): 4536.

https://doi.org/10.1182/blood.V104.11.4536.4536

Published: 2004

NARROW

CD47 Expression Defines the Efficacy of Rituximab in Non-Germinal Center B-Cell (non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Temsirolimus, An mTOR Inhibitor, In Combination with Low-Dose Clofarabine in Older Patients with Advanced Acute Myeloid Leukemia: Results of a Phase 2 GIMEMA Study (AML-1107)

Flow-Cytometric Minimal Residual Disease Determination Is a Surrogate Prognosticator in Adult AML Patients Lacking Specific Molecular Signatures.

Detection of Minimal Residual Disease by Flow-Cytometry Otimizes Risk Stratification When Combined with Cytogenetics in AML.

Hepatitis B Virus Reactivation and Alemtuzumab Therapy.

Assessment of the Frequency of Additional Malignancies in Patients with Splenic Marginal Zone Lymphoma (SMZL).

Email alerts

ASH Publications

American Society of Hematology

CD47 Expression Defines the Efficacy of Rituximab in Non-Germinal Center B-Cell (non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Temsirolimus, An mTOR Inhibitor, In Combination with Low-Dose Clofarabine in Older Patients with Advanced Acute Myeloid Leukemia: Results of a Phase 2 GIMEMA Study (AML-1107)

Flow-Cytometric Minimal Residual Disease Determination Is a Surrogate Prognosticator in Adult AML Patients Lacking Specific Molecular Signatures.

Detection of Minimal Residual Disease by Flow-Cytometry Otimizes Risk Stratification When Combined with Cytogenetics in AML.

Hepatitis B Virus Reactivation and Alemtuzumab Therapy.

Assessment of the Frequency of Additional Malignancies in Patients with Splenic Marginal Zone Lymphoma (SMZL).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only